CN1886157A - 药物组合 - Google Patents

药物组合 Download PDF

Info

Publication number
CN1886157A
CN1886157A CNA2004800355130A CN200480035513A CN1886157A CN 1886157 A CN1886157 A CN 1886157A CN A2004800355130 A CNA2004800355130 A CN A2004800355130A CN 200480035513 A CN200480035513 A CN 200480035513A CN 1886157 A CN1886157 A CN 1886157A
Authority
CN
China
Prior art keywords
arthritis
rheumatoid arthritis
combination
medicament
mtor inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800355130A
Other languages
English (en)
Chinese (zh)
Inventor
A·迈比歇尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1886157A publication Critical patent/CN1886157A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CNA2004800355130A 2003-12-01 2004-11-30 药物组合 Pending CN1886157A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0327840.5A GB0327840D0 (en) 2003-12-01 2003-12-01 Organic compounds
GB0327840.5 2003-12-01

Publications (1)

Publication Number Publication Date
CN1886157A true CN1886157A (zh) 2006-12-27

Family

ID=29798110

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800355130A Pending CN1886157A (zh) 2003-12-01 2004-11-30 药物组合

Country Status (11)

Country Link
US (1) US20070117833A1 (cg-RX-API-DMAC10.html)
EP (1) EP1819361A2 (cg-RX-API-DMAC10.html)
JP (1) JP2007512381A (cg-RX-API-DMAC10.html)
KR (1) KR20060122877A (cg-RX-API-DMAC10.html)
CN (1) CN1886157A (cg-RX-API-DMAC10.html)
AU (1) AU2004294282B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0417146A (cg-RX-API-DMAC10.html)
CA (1) CA2546738A1 (cg-RX-API-DMAC10.html)
GB (1) GB0327840D0 (cg-RX-API-DMAC10.html)
RU (1) RU2006123312A (cg-RX-API-DMAC10.html)
WO (1) WO2005053661A2 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1478648B1 (en) 2002-02-01 2014-04-30 ARIAD Pharmaceuticals, Inc. Phosphorus-containing compounds and uses thereof
WO2006053754A1 (en) * 2004-11-19 2006-05-26 Novartis Ag COMBINATIONS OF ANTI-ATHEROSCLEROTIC PEPTIDES AND AN mTOR INHIBITING AGENT AND THEIR METHODS OF USE
AU2006315512B2 (en) * 2005-11-14 2012-11-01 Ariad Pharmaceuticals, Inc. Administration of an mTOR inhibitor to treat patients with cancer
EP1880723A1 (en) * 2006-07-14 2008-01-23 Novartis AG Combination of mTOR inhibitor and antifolate compound
JP2009523149A (ja) * 2006-01-12 2009-06-18 ノバルティス アクチエンゲゼルシャフト ｍＴＯＲ阻害剤および抗葉酸化合物の組み合わせ
KR20140016439A (ko) * 2006-02-02 2014-02-07 노파르티스 아게 결절성 경화증의 치료
US20090023768A1 (en) * 2006-02-24 2009-01-22 Novartis Ag Rapamycin derivatives for treating neuroblastoma
CA2669415A1 (en) 2006-11-14 2008-05-22 Ariad Pharmaceuticals, Inc. Solid dosage form comprising ap23573

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5258389A (en) * 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
DE69624921T2 (de) * 1995-06-09 2003-09-11 Novartis Ag, Basel Rapamycinderivate
GB0123025D0 (en) * 2001-09-25 2001-11-14 Eirx Therapeutics Ltd Apoptosis
JP2005514411A (ja) * 2002-01-10 2005-05-19 ノバルティス アクチエンゲゼルシャフト ラパマイシンおよびその誘導体を含む血管疾患の予防および処置用薬剤送達システム
EP1478648B1 (en) * 2002-02-01 2014-04-30 ARIAD Pharmaceuticals, Inc. Phosphorus-containing compounds and uses thereof
WO2003106622A2 (en) * 2002-05-30 2003-12-24 The Children's Hospital Of Philadelphia Methods for treatment of acute lymphocytic leukemia
TW200902047A (en) * 2003-02-14 2009-01-16 Combinatorx Inc Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines

Also Published As

Publication number Publication date
GB0327840D0 (en) 2003-12-31
AU2004294282B2 (en) 2009-05-07
BRPI0417146A (pt) 2007-03-06
EP1819361A2 (en) 2007-08-22
RU2006123312A (ru) 2008-01-20
WO2005053661A3 (en) 2005-12-29
US20070117833A1 (en) 2007-05-24
JP2007512381A (ja) 2007-05-17
CA2546738A1 (en) 2005-06-16
AU2004294282A1 (en) 2005-06-16
WO2005053661A2 (en) 2005-06-16
KR20060122877A (ko) 2006-11-30

Similar Documents

Publication Publication Date Title
Banerjee et al. JAK–STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects
Behrens et al. MOR103, a human monoclonal antibody to granulocyte–macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial
Bruyn et al. Everolimus in patients with rheumatoid arthritis receiving concomitant methotrexate: a 3-month, double-blind, randomised, placebo-controlled, parallel-group, proof-of-concept study
CN1309421C (zh) 诸如雷帕霉素和吉西他滨或氟尿嘧啶的抗肿瘤联合
ES2701603T3 (es) Métodos de tratamiento que utilizan inhibidores selectivos de Bcl-2
Tanaka et al. JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical
US20110123543A1 (en) TNFalpha antagonists and methotrexate in the treatment of TNF-mediated disease
Flamant et al. Advances in the development of Janus kinase inhibitors in inflammatory bowel disease: future prospects
US20100160351A1 (en) Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
Battat et al. IBD matchmaking: rational combination therapy
HK1201198A1 (en) Combination therapy (vemrufenib and a mdm2 inhibitor) for the treatment proliferative disorders
CN1829532A (zh) 肌肉抑制素（gdf8）抑制剂和皮质类固醇联合用于治疗神经肌肉紊乱的用途
KR20120089250A (ko) Ｃｋ２ 조절자로 복합 요법
US20230126987A1 (en) Methods for treating cytokine storm syndrome and related diseases
KR20160044035A (ko) 류마티스성 관절염의 치료에서 또는 진통제로서 사용하기 위한 gm-csf 중화 항체
AU2004294282B2 (en) Pharmaceutical combinations
AU2017363970A1 (en) Methods of enhancing immune response with everolimus, dactolisib or both
MX2008011490A (es) Composiciones y metodos para tratar artritis reumatoide.
Choy Inhibiting interleukin-6 in rheumatoid arthritis
AU2019236714A1 (en) 7-aminocephalosporanic acid derivative as inhibitor of IL-15 and IL-2 activity
US20240197725A1 (en) Method and composition for the prevention or treatment of osteoarthritis
US11660291B2 (en) IL-8 inhibitors for use in the treatment of some sarcomas
Sorbera et al. CP-690550
MXPA06006220A (en) Pharmaceutical combinations
US20040127404A1 (en) Methods for treating autoimmune diseases

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20061227